![Domenico Valerio](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Domenico Valerio
Directeur Général chez
Stichting Administratiekantoor Endavit
Fortune : 1 M $ au 30/06/2026
Profil
Domenico Valerio is the founder of Galapagos Genomics NV, founded in 1999.
Dr. Valerio was the founder of Crucell NV, founded in 2000, and served as Chief Executive Officer.
Dr. Valerio was the founder of Aescap Venture Management BV, founded in 2005, and served as General Partner from 2005 to 2017.
Dr. Valerio was the founder of ProQR Therapeutics NV, founded in 2014, and served as Member-Supervisory Board from 2024 to 2026.
Dr. Valerio is the founder of Leyden Laboratories BV, founded in 2020, and serves as Chairman-Supervisory Board since 2020.
Current jobs include Non-Executive Director at Biocartis SA since 2012, Managing Director at Stichting Administratiekantoor Endavit, Professor at the University of Leiden since 1992, and Member-Supervisory Board at Amylon Therapeutics BV since 2017.
Former jobs include Vice Chairman-Supervisory Board at Affectis Pharmaceuticals AG, Director at Intrexon ActoBiotics NV, Director at EOS SpA, Director at Vivendy Therapeutics Ltd. from 2013 to 2014, and Non-Executive Director at Biocartis Group NV.
Education includes a graduate degree from the University of Amsterdam in 1982 and a doctorate from the University of Leiden in 1986.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PROQR THERAPEUTICS N.V. 0,69 % | 18/03/2026 | 725 692 ( 0,69 % ) | 1 M $ | 30/06/2026 |
Postes actifs de Domenico Valerio
| Sociétés | Poste | Début |
|---|---|---|
Biocartis SA
 Biocartis SA Medical SpecialtiesHealth Technology Develops molecular diagnostic instruments for immunodiagnostics | Directeur/Membre du Conseil | 01/12/2011 |
University of Leiden
 University of Leiden Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/01/1992 |
Stichting Administratiekantoor Endavit
 Stichting Administratiekantoor Endavit Investment Trusts/Mutual FundsMiscellaneous Foundation | Directeur Général | - |
Amylon Therapeutics BV
 Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Develops therapies for central nervous system | Directeur/Membre du Conseil | 01/01/2017 |
Leyden Laboratories B.V.
 Leyden Laboratories B.V. Pharmaceuticals: MajorHealth Technology Develops nasal sprays containing antibodies that target respiratory viruses | Fondateur | 01/01/2020 |
Anciens postes connus de Domenico Valerio
| Sociétés | Poste | Fin |
|---|---|---|
| PROQR THERAPEUTICS N.V. | Fondateur | 02/06/2026 |
Aescap Venture Management BV
 Aescap Venture Management BV Investment ManagersFinance Aescap's investment objective is to achieve a high rate of return for their investors while actively developing their portfolio firms' potential for commercial success. They invest in seed, start-up and early-stage biomedical firms based in Europe. They generally take majority stakes. They target firms working on treatment of human diseases. They seek a balanced portfolio composed of 15 to 20 firms. Within the biomedical area, Aescap looks for firms with marketplace leadership potential at a worldwide level. They prefer to invest in products which are sufficiently mature to yield realistic opportunities in the marketplace as well as assuring cash flow from licensing deals. Aescap is an active, hands-on investment partner. They work closely with the portfolio firm's management team to optimize human resources to build the business around innovative research. Aescap generally invests over a time frame of three to six years, depending on the type of investment. They seek transparency in legal and IP structure. | Fondateur | 31/12/2017 |
Vivendy Therapeutics Ltd.
 Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Develops enzyme replacement therapy and biological products | Directeur/Membre du Conseil | 10/03/2014 |
Galapagos Genomics NV
 Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Develops drugs | Fondateur | - |
| ░░░░░░░░░ ░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Domenico Valerio
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
74
Relations au 1er degré
15
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 15 |
|---|---|
Crucell NV
 Crucell NV Pharmaceuticals: MajorHealth Technology Develops, produces and markets vaccines, proteins and antibodies | Health Technology |
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Develops drugs | Health Technology |
University of Amsterdam
 University of Amsterdam Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Affectis Pharmaceuticals AG
 Affectis Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for the treatment of neurodegenerative and neuroinflammatory diseases | Health Technology |
University of Leiden
University of Leiden Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Intrexon ActoBiotics NV
 Intrexon ActoBiotics NV BiotechnologyHealth Technology Manufactures biopharmaceutical products | Health Technology |
Aescap Venture Management BV
Aescap Venture Management BV Investment ManagersFinance Aescap's investment objective is to achieve a high rate of return for their investors while actively developing their portfolio firms' potential for commercial success. They invest in seed, start-up and early-stage biomedical firms based in Europe. They generally take majority stakes. They target firms working on treatment of human diseases. They seek a balanced portfolio composed of 15 to 20 firms. Within the biomedical area, Aescap looks for firms with marketplace leadership potential at a worldwide level. They prefer to invest in products which are sufficiently mature to yield realistic opportunities in the marketplace as well as assuring cash flow from licensing deals. Aescap is an active, hands-on investment partner. They work closely with the portfolio firm's management team to optimize human resources to build the business around innovative research. Aescap generally invests over a time frame of three to six years, depending on the type of investment. They seek transparency in legal and IP structure. | Finance |
EOS SpA
 EOS SpA Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
Vivendy Therapeutics Ltd.
Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Develops enzyme replacement therapy and biological products | Health Services |
Biocartis SA
Biocartis SA Medical SpecialtiesHealth Technology Develops molecular diagnostic instruments for immunodiagnostics | Health Technology |
ProQR Therapeutics NV
 ProQR Therapeutics NV Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company with interest in the discovery and development of therapeutics for the treatment of genetic disorders | Health Technology |
Stichting Administratiekantoor Endavit
Stichting Administratiekantoor Endavit Investment Trusts/Mutual FundsMiscellaneous Foundation | Miscellaneous |
Biocartis Group NV
 Biocartis Group NV Medical SpecialtiesHealth Technology Develops molecular diagnostic instruments for immunodiagnostics | Health Technology |
Amylon Therapeutics BV
Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Develops therapies for central nervous system | Health Technology |
Leyden Laboratories B.V.
Leyden Laboratories B.V. Pharmaceuticals: MajorHealth Technology Develops nasal sprays containing antibodies that target respiratory viruses | Health Technology |
